Difference between revisions of "Ferrario CM, et al, Circulation (2005), cited as Ref 20 in DOI: 10.1007/s11886-020-01293-2 (Q11014)"
Jump to navigation
Jump to search
(Created claim: Fourth Author string (P152): Averill DB, #quickstatements; #temporary_batch_1592835703983) |
(Created claim: Fifth Author string (P153): Brosnihan KB, #quickstatements; #temporary_batch_1592835784350) |
||
| Property / Fifth Author string | |||
| + | Brosnihan KB | ||
| Property / Fifth Author string: Brosnihan KB / rank | |||
| + | Normal rank | ||
Revision as of 14:23, 22 June 2020
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Ferrario CM, et al, Circulation (2005), cited as Ref 20 in DOI: 10.1007/s11886-020-01293-2
|
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.
|
Statements
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 (English)
0 references
2005
0 references
Ferrario CM
0 references
Jessup J
0 references
Chappell MC
0 references
Averill DB
0 references
Brosnihan KB
0 references
